leadf
logo-loader
viewMaxCyte Inc

MaxCyte subsidiary CARMA to present MCY-M11 candidate data at meeting of Society for Immunotherapy of Cancer

MCY-M11 is currently under Phase I clinical evaluation for the treatment of advanced ovarian cancer and malignant peritoneal mesothelioma, a type of cancer that forms in the lining of the abdomen and is often caused by asbestos fibres

MaxCyte Inc - MaxCyte subsidiary CARMA Cell Therapies to present MCY-M11 candidate data at SITC meeting

MaxCyte Inc (LON:MXCT) has said its subsidiary, CARMA Cell Therapies, will share the results of a detailed phenotypic and functional characterisation of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate, at the Society for Immunotherapy of Cancer's (SITC) 35th anniversary meeting.

The life sciences company said the Virtual Scientific Program will begin on Monday and run through to November 14, with the ePoster entitled “MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro," to be presented during SITC's Poster Symposium with a live Q&A on November 12 from 4:50-5:20pm eastern time and on Saturday, November 14 from 1:00-1:30pm EST.

READ: Growing MaxCyte bolsters leadership team with three senior appointments

MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy candidate manufactured using unstimulated peripheral blood mononuclear cells (PBMCs) and is currently under Phase I clinical evaluation for the treatment of advanced ovarian cancer and malignant peritoneal mesothelioma, a type of cancer that forms in the lining of the abdomen and is often caused by asbestos fibres.

"We are encouraged by these in vitro findings, which demonstrate MCY-M11's potential to enable a long-term antitumor response. This work brings us one step closer to understanding the mechanism of action of MCY-M11 and provides strong non-clinical rationale for its use as a cancer cell therapy", CARMA’s vice-president of non-clinical and translational studies Dhana Chinnasamy said in a statement.

Shares in MaxCyte were 1.4% higher at 441p in mid-afternoon trading on Monday.

Quick facts: MaxCyte Inc

Price: 980 GBX

AIM:MXCT
Market: AIM
Market Cap: £828.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

on 1/10/20

2 min read